Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2021-11-19 00:00:00 ET · period of report 2021-11-18 · accession 0001209191-21-065993 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-19 | 2021-11-18 | QNCX | Lynch Casey | CEO, Dir | M - OptEx | $0.46 | +60.0K | 109.9K | +120% | +$27.6K |
| D | 2021-11-19 | 2021-11-18 | QNCX | Lynch Casey | CEO, Dir | M - OptEx | $0.00 | -60.0K | 23.2K | -72% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-18 | M | A | 60,000 | $0.46 | 109,895 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-11-18 | M | D | 60,000 | $0.00 | 23,159 | D | $0.46 · — to 2027-06-01 | 60,000 Common Stock | (F3) The option vested as to 1/48th of the shares on July 13, 2017, and the remaining shares vested in equal monthly installments from August 13, 2017 and ended on June 13, 2021. (F4) The expiration date of this option was erroneously reported as 06/0/1/2022 on the Form 3 filed on May 8, 2019. |